Study of Antibody Responses After a Dose of Tetravalent Meningococcal Diphtheria Conjugate Vaccine in Children
Primary Purpose
Meningitis, Meningococcemia
Status
Completed
Phase
Phase 2
Locations
United Kingdom
Study Type
Interventional
Intervention
Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Haemophilus Influenzae Type b (Hib) vaccine
Sponsored by
About this trial
This is an interventional prevention trial for Meningitis focused on measuring Meningitis, Meningococcemia, Neisseria meningitidis
Eligibility Criteria
Inclusion Criteria :
- Participant is healthy, as determined by medical history and physical examination.
- Participant is 2 years to < 5 years of age at the time of vaccination.
- At least one year from primary vaccination with a monovalent meningococcal C conjugate vaccine has elapsed.
- Parent/Guardian has signed an Ethics Committee-approved informed consent form. A culturally appropriate translation will be used for non-English speaking participants where required.
Exclusion Criteria :
- Serious chronic disease (i.e. cardiac, renal, neurologic, metabolic, rheumatologic, etc.)
- Known or suspected impairment of immunologic function
- Acute medical illness with or without fever within the last 72 hours or an axillary temperature ≥ 37.5ºC at the time of inclusion
- History of documented invasive meningococcal disease
- Administration of immune globulin, other blood products within the last three months, injected or oral corticosteroids or other immunomodulatory therapy within six weeks of the study vaccine. Individuals on a tapering dose schedule of oral steroids lasting < 7 days may be included in the trial as long as they have not received more than one course within the last two weeks prior to enrolment
- Antibiotic therapy within the 72 hours prior to vaccination or 72 hours prior to drawing any blood sample
- Received any vaccine in the 28-day period prior to enrolment, or scheduled to receive any vaccine during enrolment in the trial
- Received a meningococcal C conjugate vaccine within one year prior to enrolment
- Suspected or known hypersensitivity to any of the vaccine components
- Unavailable for the entire study period or unable to attend the scheduled visits or to comply with the study procedures
- Enrolled in another clinical trial
- Any condition, which, in the opinion of the investigator, would pose a health risk to the participant or interfere with the evaluation of the vaccine.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Menactra® Vaccine Group
Hiberix® Vaccine Group
Arm Description
Participants receiving the tetravalent (A, C, Y, and W 135) meningococcal diphtheria toxoid conjugate vaccine
Participants receiving Haemophilus Influenzae Type b (Hib) vaccine
Outcomes
Primary Outcome Measures
Geometric Mean of Antibody Titers (GMTs) as Measured by Serum Bactericidal Assay (SBA) at Baseline (Day 0) and Day 28 Post-vaccination.
Secondary Outcome Measures
Participants With a ≥ 4-Fold Rise in Antibody Titers as Measured by Serum Bactericidal Assay (SBA) From Baseline to Day 28 Post-vaccination.
Full Information
NCT ID
NCT00771849
First Posted
October 13, 2008
Last Updated
April 12, 2016
Sponsor
Sanofi Pasteur, a Sanofi Company
1. Study Identification
Unique Protocol Identification Number
NCT00771849
Brief Title
Study of Antibody Responses After a Dose of Tetravalent Meningococcal Diphtheria Conjugate Vaccine in Children
Official Title
Antibody Responses for Serogroup C After One Dose of an Experimental Tetravalent (A, C, Y, and W-135) Meningococcal Diphtheria Toxoid Conjugate Vaccine Versus a Non-meningococcal Control Vaccine in Children Who Have Previously Received a Monovalent Meningococcal C Conjugate Vaccine
Study Type
Interventional
2. Study Status
Record Verification Date
April 2016
Overall Recruitment Status
Completed
Study Start Date
August 2003 (undefined)
Primary Completion Date
March 2004 (Actual)
Study Completion Date
May 2004 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sanofi Pasteur, a Sanofi Company
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The study investigated safety profile and the antibody responses to an experimental tetravalent meningococcal diphtheria conjugate vaccine (Menactra®) in children who have received a monovalent meningococcal C conjugate vaccine at least one year previously.
Primary objective:
To describe and compare the Serum Bactericidal Assay (SBA) antibody response for serogroup C in participants receiving Menactra® to the serogroup C antibody response in a control group of participants receiving a licensed Haemophilus Influenzae Type b (Hib) conjugate vaccine 28 days following vaccination.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Meningitis, Meningococcemia
Keywords
Meningitis, Meningococcemia, Neisseria meningitidis
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
103 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Menactra® Vaccine Group
Arm Type
Experimental
Arm Description
Participants receiving the tetravalent (A, C, Y, and W 135) meningococcal diphtheria toxoid conjugate vaccine
Arm Title
Hiberix® Vaccine Group
Arm Type
Active Comparator
Arm Description
Participants receiving Haemophilus Influenzae Type b (Hib) vaccine
Intervention Type
Biological
Intervention Name(s)
Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Other Intervention Name(s)
Menactra®
Intervention Description
0.5 mL, Intramuscular
Intervention Type
Biological
Intervention Name(s)
Haemophilus Influenzae Type b (Hib) vaccine
Other Intervention Name(s)
Hiberix®
Intervention Description
0.5 mL, Intramuscular
Primary Outcome Measure Information:
Title
Geometric Mean of Antibody Titers (GMTs) as Measured by Serum Bactericidal Assay (SBA) at Baseline (Day 0) and Day 28 Post-vaccination.
Time Frame
Day 0 (before) and 28 days post-vaccination
Secondary Outcome Measure Information:
Title
Participants With a ≥ 4-Fold Rise in Antibody Titers as Measured by Serum Bactericidal Assay (SBA) From Baseline to Day 28 Post-vaccination.
Time Frame
28 days post-vaccination
10. Eligibility
Sex
All
Minimum Age & Unit of Time
2 Years
Maximum Age & Unit of Time
4 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria :
Participant is healthy, as determined by medical history and physical examination.
Participant is 2 years to < 5 years of age at the time of vaccination.
At least one year from primary vaccination with a monovalent meningococcal C conjugate vaccine has elapsed.
Parent/Guardian has signed an Ethics Committee-approved informed consent form. A culturally appropriate translation will be used for non-English speaking participants where required.
Exclusion Criteria :
Serious chronic disease (i.e. cardiac, renal, neurologic, metabolic, rheumatologic, etc.)
Known or suspected impairment of immunologic function
Acute medical illness with or without fever within the last 72 hours or an axillary temperature ≥ 37.5ºC at the time of inclusion
History of documented invasive meningococcal disease
Administration of immune globulin, other blood products within the last three months, injected or oral corticosteroids or other immunomodulatory therapy within six weeks of the study vaccine. Individuals on a tapering dose schedule of oral steroids lasting < 7 days may be included in the trial as long as they have not received more than one course within the last two weeks prior to enrolment
Antibiotic therapy within the 72 hours prior to vaccination or 72 hours prior to drawing any blood sample
Received any vaccine in the 28-day period prior to enrolment, or scheduled to receive any vaccine during enrolment in the trial
Received a meningococcal C conjugate vaccine within one year prior to enrolment
Suspected or known hypersensitivity to any of the vaccine components
Unavailable for the entire study period or unable to attend the scheduled visits or to comply with the study procedures
Enrolled in another clinical trial
Any condition, which, in the opinion of the investigator, would pose a health risk to the participant or interfere with the evaluation of the vaccine.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Monitor
Organizational Affiliation
Sanofi Pasteur Inc.
Official's Role
Study Director
Facility Information:
City
London
ZIP/Postal Code
E1 1BB
Country
United Kingdom
City
London
ZIP/Postal Code
SW17 ORE
Country
United Kingdom
12. IPD Sharing Statement
Citations:
PubMed Identifier
16417952
Citation
El Bashir H, Heath PT, Papa T, Ruggeberg JU, Johnson N, Sinha R, Balfour G, Booy R. Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine. Vaccine. 2006 Mar 24;24(14):2544-9. doi: 10.1016/j.vaccine.2005.12.018. Epub 2005 Dec 27.
Results Reference
result
Links:
URL
http://www.sanofipasteur.com
Description
Related Info
Learn more about this trial
Study of Antibody Responses After a Dose of Tetravalent Meningococcal Diphtheria Conjugate Vaccine in Children
We'll reach out to this number within 24 hrs